MedTrace Logo

Frameshift Peptides of Children With NF1

NCT04212351 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-08-31

No results posted yet for this study

Summary

The objective of this study is to determine if children and young adults with Neurofibromatosis Type 1 (NF1) and either Low Grade Gliomas (LGGs) or Plexiform Neurofibromas (PNs) have a specific frameshift peptide protein profile and whether a disease specific vaccine created to address these frameshift mutations and variants can be developed. Three study populations will be analyzed; patients with NF1 and active LGGs, NF1 and active PNs, and NF1 and no evidence of active LGGs or PNs. Participation involves a onetime blood draw.

Conditions

  • Neurofibromatosis Type 1

Interventions

GENETIC

Frameshift Array blood sample test

Patient blood test samples will be collected and evaluated for frameshift peptide mutations.

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    collaborator OTHER

  • Arizona State University

    collaborator OTHER

  • Emory University

    collaborator OTHER

  • Children's National Research Institute

    lead OTHER

Principal Investigators

  • Roger J. Packer, MD · Children's National Research Institute

Eligibility

Min Age
1 Day
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-11
Primary Completion
2022-04-27
Completion
2022-04-27

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04212351 on ClinicalTrials.gov